


PKG inhibitor peptide

Cat. No.:	HY-P1292
CAS No.:	82801-73-8
Molecular Formula:	C ₃₈ H ₇₄ N ₁₈ O ₁₀
Molecular Weight:	943.11
Sequence Shortening:	RKRARKE
Target:	Others
Pathway:	Others
Storage:	Sealed storage, away from moisture
	Powder -80°C 2 years
	-20°C 1 year



* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

SOLVENT & SOLUBILITY

In Vitro	H ₂ O : 100 mg/mL (106.03 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass			
			1 mg	5 mg	10 mg	
			1 mM	1.0603 mL	5.3016 mL	10.6032 mL
			5 mM	0.2121 mL	1.0603 mL	2.1206 mL
10 mM	0.1060 mL	0.5302 mL	1.0603 mL			
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: PBS Solubility: 100 mg/mL (106.03 mM); Clear solution; Need ultrasonic					

BIOLOGICAL ACTIVITY

Description	PKG inhibitor peptide is an ATP-competitive inhibitor of cGMP-dependent protein kinase (PKG), with a K _i of 86 μM ^[1] .
IC ₅₀ & Target	Ki: 86 μM (PKG) ^[1]
In Vitro	Summary of experiments showing that intracellular dialysis of postsynaptic cells with PKG inhibitor PKG inhibitor peptide (1 mM) failed to alter the induction of long-term depression (CCh-LTD) ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Bhatnagar D, et al. Synthetic peptide analogues differentially alter the binding affinities of cyclic nucleotide dependent protein kinases for nucleotide substrates. *Biochemistry*. 1988 Mar 22;27(6):1988-94.

[2]. Chiung-Chun Huang, et al. Activation of muscarinic acetylcholine receptors induces a nitric oxide-dependent long-term depression in rat medial prefrontal cortex. *Cereb Cortex*. 2010 Apr;20(4):982-96.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA